The bill creates a new emergency insulin program by adding sections 1–3 to chapter 70.330 RCW and places the program under the existing prescription drug purchasing consortium in RCW 70.14.060. Starting January 1, 2026, eligible Washington residents who have less than a seven-day supply of insulin on hand may obtain one emergency 30-day supply within a 12‑month period for a maximum out‑of‑pocket cost of $10. The health care authority must establish an attestation process and issue electronic vouchers for use at contracted network pharmacies. Under the bill, network pharmacies contracted with the consortium must accept the vouchers, may collect a dispensing fee of up to $10, and submit reimbursement claims to the consortium. The consortium must reimburse pharmacies within 30 days of a claim and must invoice insulin manufacturers at least quarterly for the costs it reimbursed; manufacturers must remit payment to the consortium within 30 days of receiving an invoice. The authority must publish information on manufacturer patient assistance programs and adopt any rules necessary to implement the program. The bill authorizes administrative enforcement by allowing the authority to assess fines of up to $10,000 for each manufacturer failure to remit payment; fines are subject to review under the Administrative Procedure Act (chapter 34.05 RCW) and must be deposited into the state health care affordability account (RCW 43.71.130). Defined terms include the health care authority, manufacturers of self‑administered outpatient insulin sold in or into Washington, and network pharmacies as defined in RCW 18.64.011 and contracted with the consortium. The text does not specify how the consortium initially funds reimbursements before invoicing manufacturers, the technical form of the electronic voucher or attestation, how reimbursement amounts for insulin are calculated, enforcement or collection procedures beyond the described fines, or operational governance details of the consortium found in RCW 70.14.060.

Starting January 1, 2026, the bill would let qualifying Washington residents who have less than a seven‑day supply of insulin get one emergency 30‑day supply per year for a maximum out‑of‑pocket cost of $10 by using an electronic voucher from the health care authority; pharmacies in the consortium must accept the voucher, may collect up to a $10 dispensing fee, and will submit claims to the state consortium for reimbursement within 30 days. In practice this will lower immediate costs and reduce short‑term access barriers for patients but shift cash‑flow and administrative work to pharmacies and the state consortium while insulin manufacturers are billed afterwards. The biggest effects fall on patients (cheaper emergency access), network pharmacies (new obligation to accept vouchers, administrative claims work, and potential short delays in getting paid), the prescription drug purchasing consortium and Health Care Authority (responsible for creating attestations/vouchers, reimbursing pharmacies, invoicing manufacturers, and writing implementing rules), and insulin manufacturers (required to remit payments within 30 days or face fines up to $10,000 per failure). Important operational details are missing here, including how the consortium will fund initial reimbursements, how reimbursement amounts are set, and the exact form of the attestation and electronic voucher.